{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:57:21Z","timestamp":1793372241612,"version":"4.5.0"},"reference-count":129,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Colorectal cancer (CRC), particularly the immunologically \u201ccold\u201d microsatellite-stable (MSS) subtype, remains profoundly resistant to immune checkpoint inhibitors. Antibody-drug conjugates (ADCs) are rapidly emerging as a transformative therapeutic modality poised to overcome this challenge. This review reframes ADCs beyond their role as targeted cytotoxics, repositioning them as sophisticated immuno-oncology agents. The central thesis is that by strategically selecting payloads such as topoisomerase inhibitors or auristatins, modern ADCs can induce immunogenic cell death (ICD) or pyroptosis. This mechanism effectively functions as an\n                    <jats:italic>in situ<\/jats:italic>\n                    vaccine, transforming the tumor microenvironment from \u201ccold\u201d to \u201chot\u201d by promoting dendritic cell activation and T-cell infiltration. We provide a comprehensive overview of the ADC landscape, examining key targets on bulk tumor cells (CEACAM5, HER2), cancer stem cells (LGR5, GPR56), and stromal components. We conclude that the future of ADCs in CRC lies in their rational application as immune-priming agents, creating powerful synergies in combination with checkpoint inhibitors to break therapeutic resistance and durably improve patient outcomes.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1678907","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:23:53Z","timestamp":1762151033000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":62,"title":["Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies"],"prefix":"10.3389","volume":"16","author":[{"given":"Yihan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengshan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0189-8","article-title":"Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies","volume":"16","author":"Keum","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327736","article-title":"Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN","volume":"72","author":"Morgan","year":"2023","journal-title":"Gut"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02115-4","article-title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer","volume":"29","author":"Kotani","year":"2023","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado1641","article-title":"Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer","volume":"17","author":"Grassi","year":"2025","journal-title":"Sci Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3637","article-title":"Patient-derived organoids from multiple colorectal cancer liver metastases reveal moderate intra-patient pharmacotranscriptomic heterogeneity","volume":"26","author":"Bruun","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41571-025-01059-1","article-title":"Understanding and overcoming multidrug resistance in cancer","volume":"22","author":"Ge","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21705","article-title":"Antibody\u2013drug conjugates: Smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA: Cancer J Clin"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4557","article-title":"FDA approval summary: fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3119","article-title":"FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer","volume":"27","author":"Wahby","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4161\/mabs.22854","article-title":"Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates","volume":"5","author":"Ritchie","year":"2013","journal-title":"mAbs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"mAbs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.molimm.2015.04.002","article-title":"Mechanisms of action of therapeutic antibodies for cancer","volume":"67","author":"Redman","year":"2015","journal-title":"Mol Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195823","article-title":"Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate","volume":"13","author":"Herbener","year":"2018","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"122798","DOI":"10.1016\/j.biomaterials.2024.122798","article-title":"A single-chain fab derived drug conjugate for HER2 specific delivery","volume":"313","author":"Xu","year":"2025","journal-title":"Biomaterials"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.3390\/biomedicines11113080","article-title":"Lysosomal-cleavable peptide linkers in antibody\u2013drug conjugates","volume":"11","author":"Balamkundu","year":"2023","journal-title":"J Biomedicines"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody\u2013drug conjugates for cancer therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules (Basel Switzerland)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S344052","article-title":"Dynamics of endocytosis and degradation of antibody-drug conjugate T-DM1 in HER2 positive cancer cells","volume":"15","author":"Liang","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1846714","article-title":"An overview of process development for antibody-drug conjugates produced by chemical conjugation technology","volume":"21","author":"Matsuda","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2018.07.005","article-title":"Improvement of antibody affinity by introduction of basic amino acid residues into the framework region","volume":"15","author":"Fukunaga","year":"2018","journal-title":"Biochem biophysics Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-1-4939-9929-3_3","article-title":"Conjugations to Endogenous Cysteine Residues, Methods in molecular biology","volume":"2078","author":"Nadkarni","year":"2020","journal-title":"(Clifton N.J.)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201608292","article-title":"Orthogonal cysteine protection enables homogeneous multi-drug antibody-drug conjugates","volume":"56","author":"Levengood","year":"2017","journal-title":"Angew Chem Int Ed Engl"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of drug\u2013antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody\u2013maytansinoid conjugates","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjugate Chem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202412974","article-title":"Rejuvenation of tumor-specific T cells via ultrahigh DAR antibody-polymeric imidazoquinoline complexes: coordinated targeting of PDL1 and efficient TLR7\/8 activation in intratumoral dendritic cells","volume":"37","author":"Chu","year":"2025","journal-title":"Advanced materials (Deerfield Beach Fla.)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M510026200","article-title":"Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates","volume":"281","author":"Sutherland","year":"2006","journal-title":"J Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: fact or fiction","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1525","article-title":"The mode of action and clinical outcomes of sacituzumab govitecan in solid tumors","volume":"31","author":"Tolaney","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007572","article-title":"SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models","volume":"11","author":"Gray","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(03)00510-0","article-title":"DNA damage-triggered apoptosis: critical role of DNA repair, double-strand breaks, cell proliferation and signaling","volume":"66","author":"Kaina","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.008","article-title":"Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect","volume":"102","author":"Gerber","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s magic bullet concept: 100 years of progress, Nature reviews","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104090","article-title":"Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2","volume":"190","author":"Schlam","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2007.04.010","article-title":"Cell killing by antibody-drug conjugates","volume":"255","author":"Kovtun","year":"2007","journal-title":"Cancer Lett"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2285996","article-title":"The endosomal-lysosomal system in ADC design and cancer therapy","volume":"23","author":"Leyton","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1002\/mog2.46","article-title":"Microtubule-targeting agents for cancer treatment: Seven binding sites and three strategies","volume":"2","author":"Wang","year":"2023","journal-title":"MedComm-Oncology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17060958","article-title":"Opportunities and challenges in antibody-drug conjugates for cancer therapy: A new era for cancer treatment","volume":"17","author":"Buyukgolcigezli","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"114408","DOI":"10.1016\/j.biopha.2023.114408","article-title":"A comprehensive review of key factors affecting the efficacy of antibody drug conjugate","volume":"161","author":"Samantasinghar","year":"2023","journal-title":"Biomedicine pharmacotherapy = Biomedecine pharmacotherapie"},{"key":"B45","doi-asserted-by":"publisher","first-page":"113738","DOI":"10.1016\/j.jconrel.2025.113738","article-title":"Enhancing the bystander effect of antibody-drug conjugate by using a novel caspase-3 cleavable peptide linker to overcome tumor heterogeneity","volume":"382","author":"Lee","year":"2025","journal-title":"J Control Release"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"M\u00fcller","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"102395","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicolo","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2021.04.011","article-title":"Impact of anti-HER2 treatments combined with atezolizumab on the tumor immune microenvironment in early or metastatic breast cancer: results from a phase ib study","volume":"21","author":"Hamilton","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10549-021-06423-0","article-title":"Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies","volume":"191","author":"Torres","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126598","article-title":"U3\u20131402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation","volume":"130","author":"Haratani","year":"2020","journal-title":"J Clin Invest"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1745","article-title":"A novel HER3-targeting antibody-drug conjugate, U3-1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization","volume":"25","author":"Hashimoto","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10585-014-9688-8","article-title":"T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2","volume":"32","author":"Nicoletti","year":"2015","journal-title":"Clin Exp metastasis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e000860","DOI":"10.1136\/jitc-2020-000860","article-title":"CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity","volume":"8","author":"Zammarchi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41419-019-1980-8","article-title":"An anti-CD103 antibody-drug conjugate prolongs the survival of pancreatic islet allografts in mice","volume":"10","author":"Xue","year":"2019","journal-title":"Cell Death Dis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"315ra188","DOI":"10.1126\/scitranslmed.aac4925","article-title":"Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4\/PD-1 blockade","volume":"7","author":"M\u00fcller","year":"2015","journal-title":"Sci Transl Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.62347\/GMRV6636","article-title":"HER2-positive, RAS-mutant, MSS colorectal cancer: a rare subtype report and novel insights into immunotherapy and ADC combinations","volume":"15","author":"Kong","year":"2025","journal-title":"Am J Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e389574","DOI":"10.1200\/EDBK_389574","article-title":"Update on emerging therapies for advanced colorectal cancer","volume":"43","author":"Alese","year":"2023","journal-title":"ASCO Educ Book"},{"key":"B60","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41419-024-06572-2","article-title":"Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis"},{"key":"B61","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41419-023-06073-8","article-title":"A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway","volume":"14","author":"Wu","year":"2023","journal-title":"Cell Death Dis"},{"key":"B62","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41523-023-00522-5","article-title":"Phase I study of A166, an antibody\u2013drug conjugate in advanced HER2-expressing solid tumours","volume":"9","author":"Zhang","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.9011","article-title":"Phase I\/II trial of labetuzumab govitecan (Anti-CEACAM5\/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer","volume":"35","author":"Dotan","year":"2017","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03843-z","article-title":"Precemtabart tocentecan, an anti-CEACAM5 antibody\u2013drug conjugate, in metastatic colorectal cancer: a phase 1 trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-023-01200-9","article-title":"A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity","volume":"45","author":"Zhu","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.2174\/0115680096260614231115192343","article-title":"CT109-SN-38, a novel antibody-drug conjugate with dual specificity for CEACAM5 and 6, elicits potent killing of pancreatic cancer cells","volume":"24","author":"Cardenas","year":"2024","journal-title":"Curr Cancer Drug Targets"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-23-C001","article-title":"Abstract C001: Retrospective analysis of TROP2 expression in colorectal cancer (CRC) primary tumors and liver metastases (LM) and its correlation with clinical factors","volume":"22","author":"Lentz","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/2056-4538.12394","article-title":"TROP2 in colorectal carcinoma: associations with histopathology, molecular phenotype, and patient prognosis, The journal of pathology","volume":"10","author":"Foersch","year":"2024","journal-title":"Clin Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1158\/1535-7163.MCT-24-0444","article-title":"Broad-spectrum efficacy of CEACAM6-targeted antibody-drug conjugate with BET protein degrader in colorectal","volume":"24","author":"Kogai","year":"2025","journal-title":"Lung Breast Cancer Mouse Models Mol Cancer Ther"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0452","article-title":"U3-1402, a novel HER3-targeting antibody-drug conjugate, for the treatment of colorectal cancer","volume":"18","author":"Koganemaru","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202300377","article-title":"Organic-solvent-free \u201cLego-like\u201d Modular preparation of fab-nondestructive antibody-drug conjugates with ultrahigh drug-to-antibody ratio","volume":"35","author":"Liu","year":"2023","journal-title":"Advanced materials (Deerfield Beach Fla.)"},{"key":"B72","doi-asserted-by":"publisher","first-page":"122285","DOI":"10.1016\/j.biomaterials.2023.122285","article-title":"Preparation of an Ultrahigh-DAR PDL1 monoclonal antibody-polymeric-SN38 conjugate for precise colon cancer therapy","volume":"301","author":"Zhang","year":"2023","journal-title":"Biomaterials"},{"key":"B73","doi-asserted-by":"publisher","first-page":"142844","DOI":"10.1016\/j.ijbiomac.2025.142844","article-title":"Generation and characterization of 7DC-DM1: a non-cleavable CD47-targeting antibody-drug conjugates with antitumor effects","volume":"310","author":"Chiang","year":"2025","journal-title":"Int J Biol macromolecules"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-1102","article-title":"Preclinical antitumor activity and biodistribution of a novel anti-GCC antibody-drug conjugate in patient-derived xenografts","volume":"19","author":"Abu-Yousif","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B75","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00280-023-04507-w","article-title":"A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C","volume":"91","author":"Kim","year":"2023","journal-title":"Cancer Chemother Pharmacol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12520","article-title":"Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma","volume":"13","author":"Tao","year":"2019","journal-title":"Mol Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"102158","DOI":"10.1016\/j.xcrm.2025.102158","article-title":"Combined therapy with DR5-targeting antibody-drug conjugate and CDK inhibitors as a strategy for advanced colorectal cancer, Cell reports","volume":"6","author":"Zhou","year":"2025","journal-title":"Medicine"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0915","article-title":"Preclinical evaluation of IMGC936, a next-generation maytansinoid-based antibody-drug conjugate targeting ADAM9-expressing","volume":"21","author":"Scribner","year":"2022","journal-title":"Tumors Mol Cancer Ther"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1051506","article-title":"DOG1 as a novel antibody-drug conjugate target for the treatment of multiple gastrointestinal tumors and liver metastasis","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0401","article-title":"SGN-CD228A is an investigational CD228-directed antibody-drug conjugate with potent antitumor activity across a wide spectrum of preclinical solid tumor models","volume":"22","author":"Mazahreh","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1038\/s41598-025-85856-9","article-title":"EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells","volume":"15","author":"Jafary","year":"2025","journal-title":"Sci Rep"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3390\/cancers16071256","article-title":"EGFR-targeted antibody-drug conjugate to different aminobisphosphonates: direct and indirect antitumor effects on colorectal carcinoma cells","volume":"16","author":"Pisheh","year":"2024","journal-title":"Cancers"},{"key":"B83","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2174\/1574892815666201221121859","article-title":"Anti-EGFR-mAb and 5-fluorouracil conjugated polymeric nanoparticles for colorectal cancer","volume":"16","author":"Bhattacharya","year":"2021","journal-title":"Recent patents anti-cancer Drug Discov"},{"key":"B84","doi-asserted-by":"publisher","first-page":"314ra186","DOI":"10.1126\/scitranslmed.aac7433","article-title":"Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer","volume":"7","author":"Junttila","year":"2015","journal-title":"Sci Transl Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15122763","article-title":"Colorectal cancer stem cells and targeted agents","volume":"15","author":"Zhao","year":"2023","journal-title":"Pharmaceutics"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00359-0","article-title":"Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR \u00d7 LGR5 bispecific antibody with efficacy in epithelial tumors","volume":"3","author":"Herpers","year":"2022","journal-title":"Nat Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17101665","article-title":"Petosemtamab, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and leucine-rich G repeat-containing protein-coupled receptor (LGR5) designed for broad clinical applications","volume":"17","author":"Lundberg","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3390\/ijms23031200","article-title":"Antibody conjugated PLGA nanocarriers and superparmagnetic nanoparticles for targeted delivery of oxaliplatin to cells from colorectal carcinoma","volume":"23","author":"Zumaya","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1039\/D1RA01093J","article-title":"Gold nanoparticles conjugated with anti-CD133 monoclonal antibody and 5-fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting","volume":"11","author":"Mohd-Zahid","year":"2021","journal-title":"RSC Adv"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02192-3","article-title":"An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer","volume":"128","author":"Jacob","year":"2023","journal-title":"Br J Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.2174\/0113894501298344240507080149","article-title":"GPR56, an adhesion GPCR with multiple roles in human diseases, current status and future perspective","volume":"25","author":"Fan","year":"2024","journal-title":"Curr Drug Targets"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-19-0436","article-title":"GPR56 Drives Colorectal Tumor Growth and Promotes Drug Resistance through Upregulation of MDR1 Expression via a RhoA-Mediated Mechanism","volume":"17","author":"Zhang","year":"2019","journal-title":"Mol Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-6328","article-title":"Abstract 6328: GPR56 as a therapeutic target for the development of antibody-drug conjugates for the treatment of colorectal cancer","volume":"82","author":"Francisco","year":"2022","journal-title":"Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-0798","article-title":"Antibody-drug conjugates targeting the EGFR ligand epiregulin elicit robust antitumor activity in colorectal cancer","volume":"85","author":"Jacob","year":"2025","journal-title":"Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-4251","article-title":"Abstract 4251: Development and characterization of an epiregulin antibody-drug conjugate for targeting colorectal cancer cell plasticity","volume":"82","author":"Jacob","year":"2022","journal-title":"Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"215969","DOI":"10.1016\/j.canlet.2022.215969","article-title":"Drug conjugate-based anticancer therapy - Current status and perspectives","volume":"552","author":"Yang","year":"2023","journal-title":"Cancer Lett"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.508","article-title":"Trastuzumab-emtansine (T-DM1) in HER2-amplified metastatic colorectal cancer patients progressing to trastuzumab-lapatinib: the HERACLES RESCUE phase II trial","volume":"33","author":"Sartore Bianchi","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-03887-0","article-title":"HER2-targeted therapy in colorectal cancer: a comprehensive review","volume":"27","author":"Benli","year":"2025","journal-title":"Clin Trans Oncol Off Publ Fed Spanish Oncol Societies Natl Cancer Institute Mexico"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.012","article-title":"Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study","volume":"33","author":"Gazzah","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40425-019-0575-3","article-title":"CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids","volume":"7","author":"Gonzalez-Exposito","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0437","article-title":"Improving intracellular delivery of an antibody\u2013drug conjugate targeting carcinoembryonic antigen increases efficacy at clinically relevant doses in vivo","volume":"23","author":"Nessler","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B102","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: Recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm Sinica. B"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol Ther"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody\u2013drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"5667","DOI":"10.1038\/s41467-020-19498-y","article-title":"Co-administered antibody improves penetration of antibody\u2013dye conjugate into human cancers with implications for antibody\u2013drug conjugates","volume":"11","author":"Lu","year":"2020","journal-title":"Nat Commun"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-015-1729-8","article-title":"Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates","volume":"32","author":"Xu","year":"2015","journal-title":"Pharm Res"},{"key":"B108","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.3390\/cancers15235639","article-title":"Small antibodies with big applications: nanobody-based cancer diagnostics and therapeutics","volume":"15","author":"Zhang","year":"2023","journal-title":"Cancers"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1010428317692246","DOI":"10.1177\/1010428317692246","article-title":"Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers","volume":"39","author":"Kleist","year":"2017","journal-title":"Tumour biology: J Int Soc Oncodevelopmental Biol Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-016-1956-3","article-title":"Molecular pathological classification of colorectal cancer","volume":"469","author":"M\u00fcller","year":"2016","journal-title":"Virchows Archiv: an Int J Pathol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-1397","article-title":"The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy","volume":"5","author":"Xiao","year":"2015","journal-title":"Cancer Discov"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"New Engl J Med"},{"key":"B114","article-title":"A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer","volume":"58","author":"Boland","year":"1998","journal-title":"Cancer Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0046","article-title":"Mismatch repair deficiency and response to immune checkpoint blockade","volume":"21","author":"Lee","year":"2016","journal-title":"oncologist"},{"key":"B116","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrclinonc.2016.199","article-title":"Surveillance after curative treatment for colorectal cancer","volume":"14","author":"van der Stok","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.3390\/ijms18091926","article-title":"Implications of ABCG2 expression on irinotecan treatment of colorectal cancer patients: A review","volume":"18","author":"Nielsen","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1007\/s00232-005-0792-1","article-title":"Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux","volume":"206","author":"Loo","year":"2005","journal-title":"J membrane Biol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.2174\/156800909788166493","article-title":"Multidrug resistance through the spectacle of P-glycoprotein","volume":"9","author":"Goda","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"B120","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/1756-9966-28-144","article-title":"The expression and significance of P-glycoprotein, lung resistance protein and multidrug resistance-associated protein in gastric cancer","volume":"28","author":"Hu","year":"2009","journal-title":"J Exp Clin Cancer research: CR"},{"key":"B121","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/147323001003800104","article-title":"Expression of P-glycoprotein and multidrug resistance-associated protein is associated with multidrug resistance in gastric cancer","volume":"38","author":"Xu","year":"2010","journal-title":"J Int Med Res"},{"key":"B122","doi-asserted-by":"publisher","first-page":"102213","DOI":"10.1016\/j.xcrm.2025.102213","article-title":"Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep Med"},{"key":"B123","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","article-title":"D.-C. investigators, Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer","volume":"14","author":"Yoshino","year":"2023","journal-title":"Nat Commun"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study, The Lancet","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Oncology"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14686","article-title":"Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01196-3","article-title":"Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer","volume":"24","author":"Shitara","year":"2021","journal-title":"Gastric Cancer"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.3501","article-title":"Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing\/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study","volume":"41","author":"Raghav","year":"2023","journal-title":"J Clin Oncol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"102113","DOI":"10.1016\/j.eclinm.2023.102113","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations","volume":"62","author":"D\u2019Arienzo","year":"2023","journal-title":"eClinicalMedicine"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2025.01.007","article-title":"Advancements in antibody-drug conjugates as cancer therapeutics","volume":"5","author":"Fong","year":"2025","journal-title":"J Natl Cancer Center"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1678907\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:23:54Z","timestamp":1762151034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1678907\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":129,"alternative-id":["10.3389\/fimmu.2025.1678907"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1678907","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"article-number":"1678907"}}